Transforming Growth Factor P1 and Tamoxifen Therapy in Breast Cancer
Author Information
Author(s): A.M. Thompson, D.J. Kerr, C.M. Steel
Primary Institution: Royal Infirmary, Edinburgh; Beatson Institute, Glasgow; MRC Human Genetics Unit, Edinburgh
Hypothesis
Does high expression of TGF-P1 in breast tumors correlate with the failure of tamoxifen therapy?
Conclusion
High levels of TGF-P1 mRNA in breast tumors may contribute to the failure of tamoxifen therapy.
Supporting Evidence
- TGF-P1 mRNA expression was sustained at high levels in mouse xenografts treated with tamoxifen.
- High TGF-P1 mRNA levels were found in 45 out of 56 human breast tumors.
- High expression of TGF-P1 correlated with premenopausal status.
Takeaway
This study found that a substance called TGF-P1 in breast cancer tumors might stop a medicine called tamoxifen from working.
Methodology
The study examined TGF-P1 mRNA expression in a mouse model and in breast tumor tissues from patients who received tamoxifen.
Limitations
The study does not address the mechanisms of TGF-P1 activation or receptor function.
Participant Demographics
Patients aged 34 to 84 years, with a subgroup of 11 postmenopausal women treated with tamoxifen.
Statistical Information
P-Value
0.05
Statistical Significance
p=0.05
Want to read the original?
Access the complete publication on the publisher's website